Canakinumab showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
Anakinra showed no clear difference in serious adverse events compared with standard care/placebo (low certainty).
The review found no eligible studies for this question.
The review found no eligible studies for this question.
mRNA‐1273 – ModernaTX showed no clear difference in serious adverse eventsl compared with placebo (moderate certainty).
CVnCoV – CureVac AG showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
ChAdOx1 – AstraZeneca + University of Oxford showed no clear difference in serious adverse eventso compared with placebo (moderate certainty).
SII‐ChAdOx1 – Serum Institute of India/AstraZeneca + University of… showed no clear difference in serious adverse eventsg compared with chAdOx1 – University of Oxford (low certainty).
AD26.COV2.S – Janssen Pharmaceutical Companies showed no clear difference in serious adverse eventsb compared with placebo (moderate certainty).
Gam‐COVID‐VAC – Sputnik V showed no clear difference in serious adverse eventsf compared with placebo (low certainty).
CoronaVac – Sinovac showed no clear difference in serious adverse eventsr compared with placebo (low certainty).
BNT162b2 – Pfizer/BioNTech + Fosun Pharma showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
WIBP‐CorV – Sinopharm‐Wuhan showed no clear difference in serious adverse eventsi compared with placebo (low certainty).
BBIBP‐CorV – Sinopharm‐Beijing showed no clear difference in serious adverse eventsk compared with placebo (low certainty).
BBV152 – Bharat Biotech leads to lower serious adverse eventsi compared with placebo (high certainty).
NVX‐CoV2373 – Novavax showed no clear difference in serious adverse eventsm compared with placebo (low certainty).
The review found no eligible studies for this question.